Vanda Pharmaceuticals Inc. /
Actelion Pharmaceuticals Ltd.
Vanda Pharmaceuticals Inc. acquires rights from Actelion Pharmaceuticals Ltd.
What happened
Vanda Pharmaceuticals Inc. acquired U.S. and Canadian rights to PONVORY ® (ponesimod), a treatment for adults with relapsing forms of multiple sclerosis.
Vanda paid $100 million for the rights. Janssen will continue operations during a transition period as the parties transition regulatory and supply responsibility to Vanda.
The source
Everything on this page comes from the source below.
Vanda Pharmaceuticals Inc. acquires rights from Actelion Pharmaceuticals Ltd.
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly